JP2017535258A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535258A5
JP2017535258A5 JP2017519646A JP2017519646A JP2017535258A5 JP 2017535258 A5 JP2017535258 A5 JP 2017535258A5 JP 2017519646 A JP2017519646 A JP 2017519646A JP 2017519646 A JP2017519646 A JP 2017519646A JP 2017535258 A5 JP2017535258 A5 JP 2017535258A5
Authority
JP
Japan
Prior art keywords
site
exogenous
goi
nucleic acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017519646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535258A (ja
JP6668340B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/056653 external-priority patent/WO2016064999A1/en
Publication of JP2017535258A publication Critical patent/JP2017535258A/ja
Publication of JP2017535258A5 publication Critical patent/JP2017535258A5/ja
Application granted granted Critical
Publication of JP6668340B2 publication Critical patent/JP6668340B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017519646A 2014-10-23 2015-10-21 新規cho組込み部位およびその使用 Active JP6668340B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067774P 2014-10-23 2014-10-23
US62/067,774 2014-10-23
PCT/US2015/056653 WO2016064999A1 (en) 2014-10-23 2015-10-21 Novel cho integration sites and uses thereof

Publications (3)

Publication Number Publication Date
JP2017535258A JP2017535258A (ja) 2017-11-30
JP2017535258A5 true JP2017535258A5 (enExample) 2018-11-22
JP6668340B2 JP6668340B2 (ja) 2020-03-18

Family

ID=54602002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519646A Active JP6668340B2 (ja) 2014-10-23 2015-10-21 新規cho組込み部位およびその使用

Country Status (16)

Country Link
US (5) US9816110B2 (enExample)
EP (1) EP3209785B1 (enExample)
JP (1) JP6668340B2 (enExample)
KR (1) KR102243243B1 (enExample)
CN (1) CN107109434A (enExample)
AR (1) AR102420A1 (enExample)
AU (1) AU2015335921B2 (enExample)
BR (1) BR112017008022A2 (enExample)
CA (1) CA2965495C (enExample)
EA (1) EA037255B1 (enExample)
IL (1) IL251674B (enExample)
MX (1) MX2017005306A (enExample)
MY (1) MY184103A (enExample)
SG (1) SG11201703149RA (enExample)
TW (2) TWI747808B (enExample)
WO (1) WO2016064999A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107109434A (zh) 2014-10-23 2017-08-29 瑞泽恩制药公司 新颖cho整合位点和其用途
US10329594B1 (en) 2015-09-03 2019-06-25 CHO Plus, Inc. Cell lines for high level production of protein-based pharmaceuticals
US11649449B2 (en) 2015-09-03 2023-05-16 CHO Plus, Inc. Hybrid cell lines for high level production of a target protein
SG10202010156XA (en) 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of an expression-enhancing locus
CN109195986B (zh) 2016-04-20 2023-01-03 瑞泽恩制药公司 基于使用表达增强性基因座来制备抗体的组合物和方法
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EP4130280A3 (en) * 2016-12-20 2023-04-19 Development Center for Biotechnology Targeted integration sites in chinese hamster ovary cell genome
US20210309988A1 (en) * 2017-02-07 2021-10-07 Sigma-Aldrich Co. Llc Stable targeted integration
EP3583205A1 (en) * 2017-02-17 2019-12-25 Lonza Ltd Mammalian cells for producing adeno-associated viruses
US11959093B2 (en) 2017-03-19 2024-04-16 Applied Stemcell, Inc. Integration sites and uses thereof
AU2018315428B2 (en) 2017-08-11 2024-11-14 Boehringer Ingelheim International Gmbh Integration sites in CHO cells
CN107723276B (zh) * 2017-11-02 2021-08-13 上海交通大学 一种稳定高表达目标产物的细胞株的构建方法和试剂盒
IL275462B1 (en) * 2017-12-22 2025-09-01 Genentech Inc Targeted integration of nucleic acids
CN111566208A (zh) * 2017-12-22 2020-08-21 生物辐射实验室股份有限公司 利用CRISPR/Cas基因靶向控制生物体表型
CN109321604B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006882077-1稳定表达蛋白质的应用
CN109136193B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006884764-1稳定表达蛋白质的应用
CN109207432B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006883358-1稳定表达蛋白质的应用
CN109295093B (zh) * 2018-10-30 2021-08-03 江南大学 一种cho细胞基因组内nw_006882456-1稳定表达蛋白质的应用
CN109295092B (zh) * 2018-10-30 2021-06-29 江南大学 一种cho细胞基因组内nw_003613638-1稳定表达蛋白质的应用
CN109337927B (zh) * 2018-10-30 2021-07-06 江南大学 一种cho细胞基因组内nw_006880285-1稳定表达蛋白质的应用
TW202039852A (zh) * 2018-12-21 2020-11-01 美商建南德克公司 核酸之靶向整合
IL286630B2 (en) 2019-04-02 2025-05-01 Chugai Pharmaceutical Co Ltd Method for introducing a target-specific foreign gene
WO2020264253A1 (en) 2019-06-26 2020-12-30 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
EP3901266A1 (en) * 2020-04-22 2021-10-27 LEK Pharmaceuticals d.d. Super-enhancers for recombinant gene expression in cho cells
BR112022024625A2 (pt) * 2020-06-02 2023-02-23 Catalent Pharma Solutions Llc Construtos de ácido nucleico para a fabricação de proteína
KR20230027043A (ko) * 2020-06-24 2023-02-27 제넨테크, 인크. 핵산의 표적화 통합
KR20230085929A (ko) 2020-10-15 2023-06-14 에프. 호프만-라 로슈 아게 Va rna 전사를 위한 핵산 구조체
CN113755447B (zh) * 2021-09-23 2022-04-29 云舟生物科技(广州)股份有限公司 一种用于生产腺病毒的293a细胞株及其制备与应用
US20230304062A1 (en) 2021-10-18 2023-09-28 Regeneron Pharmaceuticals, Inc. Controlled transcription of polynucleotides
CA3235566A1 (en) 2021-10-18 2023-04-27 Michael Goren Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
MX2024004647A (es) 2021-10-18 2024-05-02 Regeneron Pharma Celulas eucariotas que comprenden polinucleotidos de virus asociados a adenovirus.
MX2024009088A (es) * 2022-01-28 2024-07-31 Univ Columbia Modificaciones geneticas para xenotrasplantes.
CN117305334B (zh) * 2022-06-21 2024-11-08 深圳太力生物技术有限责任公司 靶向整合细胞及其制备方法、生产目标基因表达产物的方法
US20240167984A1 (en) 2022-11-18 2024-05-23 Regeneron Pharmaceuticals, Inc. Methods for detecting and determining protein structures and stability in fluids, including biological fluids
CN118726475B (zh) * 2023-03-28 2025-07-08 深圳太力生物技术有限责任公司 核酸、重组载体、靶向整合细胞、基因表达方法和应用
WO2024211287A1 (en) * 2023-04-03 2024-10-10 Seagen Inc. Production cell lines with targeted integration sites
US20250122482A1 (en) 2023-09-07 2025-04-17 Regeneron Pharmaceuticals, Inc. Production and purification of covalently surface modified adeno-associated virus
US20250163468A1 (en) 2023-11-21 2025-05-22 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US6689606B2 (en) 1998-07-21 2004-02-10 M.L. Laboratories Plc Polynucleotide
US6521419B1 (en) * 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
WO2002081632A2 (en) 2001-04-04 2002-10-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acids for transgene expression
US20040045043A1 (en) * 2002-05-20 2004-03-04 Finney Robert E. Compositions and methods for generating conditional knockouts
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
ES2522615T3 (es) 2007-06-04 2014-11-17 Regeneron Pharmaceuticals, Inc. Regiones de expresión y estabilidad potenciadas
AU2009322964B2 (en) * 2008-12-04 2014-10-09 Sangamo Therapeutics, Inc. Genome editing in rats using zinc-finger nucleases
CA2832095A1 (en) 2011-04-05 2012-10-11 The Scripps Research Institute Chromosomal landing pads and related uses
EP2699264B1 (en) 2011-04-20 2018-03-14 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
DK2714936T3 (en) * 2011-06-01 2019-03-25 Prec Biosciences Inc METHODS AND PRODUCTS FOR PRODUCING MANIPULATED MAMMAL CELL LINES WITH AMPLIFIED TRANSGENES
JP6188703B2 (ja) * 2011-10-27 2017-08-30 サンガモ セラピューティクス, インコーポレイテッド Hprt遺伝子座を修飾するための方法および組成物
CA2871524C (en) 2012-05-07 2021-07-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
CN107109434A (zh) 2014-10-23 2017-08-29 瑞泽恩制药公司 新颖cho整合位点和其用途

Similar Documents

Publication Publication Date Title
JP2017535258A5 (enExample)
AU2016202122B2 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
KR102474757B1 (ko) 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
ES2716735T3 (es) Animales no humanos que tienen un gen del grupo de diferenciación 47 humanizado
Nozaki et al. BBS1 is involved in retrograde trafficking of ciliary GPCRs in the context of the BBSome complex
EP2627773B1 (en) Restricted immunoglobulin heavy chain mice
CN109195986B (zh) 基于使用表达增强性基因座来制备抗体的组合物和方法
JP2019514358A5 (enExample)
JP2018502583A5 (enExample)
ES2604255T3 (es) Anticuerpos contra IL-25
JP2017535258A (ja) 新規cho組込み部位およびその使用
SA518391463B1 (ar) VIII أشكال متباينة لعامل منخفضة تركيبات وطرق واستخدامات لمعالجة اضطرابات إرقاء الدم CpG،
JP2017514501A5 (enExample)
KR20010024296A (ko) 벡터 구조체와 세포 dna의 비상동 재조합법에 의한내생 유전자 발현
JP2011504721A5 (enExample)
JP2016515508A5 (enExample)
KR20190063458A (ko) Muc1에 특이적인 키메라 항원 수용체(cars) 및 그의 사용 방법
CN107207581B (zh) 用于制备优化的治疗分子的方法
CN113430207A (zh) 在免疫球蛋白重链编码序列中具有dh-dh重排能力的非人动物
CN115427558A (zh) 用于高效且特异性基因组编辑的位点-特异性重组酶的融合物
JP2016540506A5 (enExample)
Rosenfeld et al. A primer set for comprehensive amplification of V-genes from rhesus macaque origin based on repertoire sequencing
JP2015501642A5 (enExample)
CN106086070B (zh) 一种ProtoRAG转座子系统及其用途
CA3234642A1 (en) Transposases and uses thereof